enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 60,300 shares, a decrease of 31.9% from the February 13th total of 88,500 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 131,100 shares, the days-to-cover ratio is currently 0.5 days.

enGene Stock Up 0.9 %

Shares of NASDAQ ENGN opened at $5.40 on Friday. enGene has a one year low of $4.42 and a one year high of $18.40. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The firm’s 50 day simple moving average is $6.51 and its two-hundred day simple moving average is $7.11. The stock has a market capitalization of $275.28 million, a P/E ratio of -9.31 and a beta of -0.61.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. As a group, analysts expect that enGene will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ENGN shares. Piper Sandler started coverage on shares of enGene in a report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price target on the stock. UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $34.00 to $7.00 in a report on Friday, February 14th. Raymond James started coverage on shares of enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of enGene in a research note on Monday, December 23rd. Finally, Citizens Jmp raised shares of enGene to a “strong-buy” rating in a research note on Monday, November 18th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, enGene currently has a consensus rating of “Buy” and an average target price of $25.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fcpm Iii Services B.V. grew its position in enGene by 11.0% during the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock valued at $64,057,000 after acquiring an additional 954,610 shares during the last quarter. VR Adviser LLC grew its holdings in shares of enGene by 41.5% in the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after purchasing an additional 1,480,573 shares during the last quarter. Deep Track Capital LP grew its holdings in shares of enGene by 74.8% in the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock worth $30,308,000 after purchasing an additional 1,949,942 shares during the last quarter. Blue Owl Capital Holdings LP grew its holdings in shares of enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after purchasing an additional 101,006 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of enGene by 84.7% in the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock worth $8,145,000 after purchasing an additional 561,797 shares during the last quarter. 64.16% of the stock is currently owned by institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.